NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

CSV download of the complete patent data set.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset the Search Filters to go back to the initial display of all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NCI E-182-2017-0-EP-06 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION EP National Stage 18786145.5 Issued
NCI E-182-2017-0-GB-01 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION GB EP 18786145.5 Issued
NCI E-182-2017-0-CH-01 METHODS FOR SELECTIVELY EXPANDING CELLS EXPRESSING A TCR WITH A MURINE CONSTANT REGION CH EP 18786145.5 Issued
NIAID E-087-2019-0-PCT-01 NEUTRALIZING ANTIBODIES TO PLASMODIUM FALCIPARUM CIRCUMSPOROZOITE PROTEIN AND THEIR USE PCT PCT COMB PCT/US2020/031345 Expired
NIAID E-087-2019-0-EP-02 NEUTRALIZING ANTIBODIES TO PLASMODIUM FALCIPARUM CIRCUMSPOROZOITE PROTEIN AND THEIR USE EP National Stage 20727798.9 Pending
NIDCR E-485-2013-1-US-04 COMPOSITIONS AND METHODS FOR THE INHIBITION OF PRURITUS US National Stage 16/761,047 11324725 Issued PDF
NCI E-167-2017-0-AU-03 NOVEL CANCER TREATMENT UTILIZING PRE-EXISTING MICROBIAL IMMUNITY AU National Stage 2018360784 Pending
NCATS E-098-2019-0-PCT-02 SCALABLE SYNTHESIS OF DUAL-TARGET INHIBITOR OF CANNABINOID-1 RECEPTOR AND INDUCIBLE NITRIC OXIDE SYNTHASE PCT PCT PCT/US2020/030624 Expired
NHLBI E-121-2016-2-US-09 METHODS OF PRODUCING MODIFIED NATURAL KILLER CELLS AND METHODS OF USE US National Stage 16/760,760 Pending
NIDCR E-150-2019-0-US-01 Application Of AAV44.9 Vector In Gene Therapy For The Inner Ear US 63/018,140 Abandoned
NCATS E-101-2017-0-US-04 SUBSTITUTED QUINOLINE ANALOGS AS ALDEHYDEDE DEHYDROGENASE 1A1 (ALDH1A1) INHIBITORS US National Stage 16/760,345 11505559 Issued PDF
NCATS E-074-2019-0-US-02 ANTI-FLAVIVIRUS COMPOUNDS AND METHODS OF USE US CON 16/861,281 11471443 Issued PDF
NCI E-167-2017-0-US-09 CANCER TREATMENT UTILIZING PRE-EXISTING MICROBIAL IMMUNITY US National Stage 16/760,138 Abandoned
NIAID E-131-2019-0-US-01 RECOMBINANT HUMAN METAPNEUMOVIRUS F PROTEINS AND THEIR USE US 63/017,581 Abandoned
NCI E-008-2014-2-US-15 THYMIC STROMAL LYMPHOPOIETIN RECEPTOR-SPECIFIC CHIMERIC ANTIGEN RECEPTORS AND METHODS USING SAME US DIV 16/860,216 11834509 Issued PDF
NCI E-125-2021-0-US-01 Methods And Materials For Large-Scale Assessment Of Ligand Binding Selectivity Of G-Quadruplex Recognition Using Custom G4 Microarrays US 63/016,385 Abandoned
NIAID E-182-2020-4-US-01 CORONAVIRUS RNA VACCINES US 63/016,175 Abandoned
NCATS E-060-2019-0-JP-05 A Highly Efficient Nociceptor Differentiation Protocol For Human Pluripotent Stem Cells JP National Stage 2021-563214 Pending
NCATS E-060-2019-0-EP-07 NOCICEPTOR DIFFERENTIATION FROM HUMAN PLURIPOTENT STEM CELLS EP National Stage 20796132.7 Pending
NINDS E-102-2019-1-PCT-01 HIGH-RESOLUTION CEREBROSPINAL FLUID-SUPPRESSED T2*-WEIGHTED MAGNETIC RESONANCE IMAGING OF CORTICAL LESIONS PCT PCT COMB PCT/US2020/029823 Expired
NCATS E-060-2019-0-PCT-02 A Highly Efficient Nociceptor Differentiation Protocol For Human Pluripotent Stem Cells PCT PCT PCT/US2020/029721 Expired
NHLBI E-149-2020-0-US-01 PROGRAMMABLE MECHANOBIOLOGICAL PLATFORM US 63/014,981 Abandoned
NCATS E-060-2019-0-AU-06 A Highly Efficient Nociceptor Differentiation Protocol For Human Pluripotent Stem Cells AU National Stage 2020263484 Pending
NIDDK E-144-2019-1-US-01 Treatment And Prevention Of Neuropathic Pain With P2Y14 Antagonists US 63/013,792 Abandoned
NEI E-050-2015-0-US-09 RP2 AND RPGR VECTORS FOR TREATING X-LINKED RETINITIS PIGMENTOSA US DIV 16/854,605 11617801 Issued PDF
NIAID E-136-2013-0-US-13 SINGLE-DOMAIN VHH ANTIBODIES DIRECTED TO NOROVIRUS GI.1 AND GII.4 AND THEIR USE US DIV 16/854,703 11325965 Issued PDF
NHGRI E-148-2017-0-US-04 ISOTOPIC BIOMARKERS OF ORGANIC ACIDEMIAS US National Stage 16/758,009 Pending
NCI E-229-2017-0-US-03 TREATING OR PREVENTING ADVERSE LIVER CONDITIONS US National Stage 16/756,926 11771737 Issued PDF
NIAID E-186-2020-0-US-01 Nucleic Acid Vaccines Against CoVID-19 US 63/011,860 Abandoned
NIDDK E-108-2020-0-US-01 Thyclotides US 63/011,398 Abandoned
NCI E-230-2012-0-IL-59 T Cell Receptors Recognizing MHC Class II-Restricted Mage-A3 IL DIV 274003 Issued
NIAID E-240-2017-0-US-05 RECOMBINANT HIV-1 ENVELOPE PROTEINS AND THEIR USE US National Stage 16/756,777 11136356 Issued PDF
NIAID E-203-2020-0-PCT-02 COMPOSITIONS AND METHODS OF MANUFACTURING STAR POLYMERS FOR LIGAND DISPLAY AND/OR DRUG DELIVERY PCT PCT PCT/US2020/028586 Expired
NIAID E-203-2020-0-CN-07 COMPOSITIONS AND METHODS OF MANUFACTURING STAR POLYMERS FOR LIGAND DISPLAY AND/OR DRUG DELIVERY CN National Stage 202080042939.8 Pending
NIAID E-203-2020-0-EP-08 COMPOSITIONS AND METHODS OF MANUFACTURING STAR POLYMERS FOR LIGAND DISPLAY AND/OR DRUG DELIVERY EP National Stage 20724651.3 Pending
NIAID E-203-2020-0-JP-09 COMPOSITIONS AND METHODS OF MANUFACTURING STAR POLYMERS FOR LIGAND DISPLAY AND/OR DRUG DELIVERY JP National Stage 2021-562047 Pending
NIAID E-203-2020-0-CA-03 COMPOSITIONS AND METHODS OF MANUFACTURING STAR POLYMERS FOR LIGAND DISPLAY AND/OR DRUG DELIVERY CA National Stage 3137081 Pending
NIAID E-131-2020-1-US-01 Anti-Coronavirus Antibodies And Methods Of Use US 63/010,999 Abandoned
NIAID E-203-2020-0-IN-05 COMPOSITIONS AND METHODS OF MANUFACTURING STAR POLYMERS FOR LIGAND DISPLAY AND/OR DRUG DELIVERY IN National Stage 202117049363 Pending
NIAID E-203-2020-0-AU-06 COMPOSITIONS AND METHODS OF MANUFACTURING STAR POLYMERS FOR LIGAND DISPLAY AND/OR DRUG DELIVERY AU National Stage 2020260131 Pending
NIAID E-203-2020-0-KR-10 COMPOSITIONS AND METHODS OF MANUFACTURING STAR POLYMERS FOR LIGAND DISPLAY AND/OR DRUG DELIVERY KR National Stage 10-2021-7037335 Pending
NIAID E-052-2017-4-SG-48 Trispecific And/or Trivalent Binding Proteins For Prevention Or Treatment Of HIV Infection SG DIV 10202003467R Pending
NHLBI E-112-2019-0-US-02 A Principal Component Analysis Based Multi-baseline Phase Correction Method For PRF Thermometry US ORD 16/849,313 11301997 Issued PDF
NCI E-008-2018-0-US-07 OPTICAL CONFIGURATION METHODS FOR SPECTRAL SCATTER FLOW CYTOMETRY US National Stage 16/756,420 10876955 Issued PDF
NCI E-097-2017-0-US-05 Macromolecular Platform For Targeting Scavenger Receptor A1 US National Stage 16/756,259 Pending
NIAID E-116-2020-0-US-01 SARS-COV ANTIBODIES AND THEIR USE US 63/010,646 Abandoned
NIAID E-099-2016-1-US-06 USE OF GRAM NEGATIVE SPECIES TO TREAT ATOPIC DERMATITIS US CON 16/848,587 Abandoned
NCI E-013-2018-0-AU-04 Fully Human Antibody Targeting Human CD19 For Cancer Therapeutic Development AU National Stage 2018331517 Pending
NIDA E-077-2019-0-PCT-02 Novel Opotically Active Dopamine D3 Receptor Selective Agonists PCT PCT PCT/US2020/027903 Expired
NIDA E-077-2019-0-EP-05 Novel Opotically Active Dopamine D3 Receptor Selective Agonists EP National Stage 20724970.7 Pending